BACKGROUND AIMS: Heart failure therapy with human embryonic stem cell (hESC)-derived cardiomyocytes (hCM) has been limited by the low rate of spontaneous hCM differentiation. As others have shown that p38 mitogen-activated protein kinase (p38MAPK) directs neurogenesis from mouse embryonic stem cells, we investigated whether the p38MAPK inhibitor, SB203580, might influence hCM differentiation. METHODS: We treated differentiating hESC with SB203580 at specific time-points, and used flow cytometry, immunocytochemistry, quantitative real-time (RT)-polymerase chain reaction (PCR), teratoma formation and transmission electron microscopy to evaluate cardiomyocyte formation. RESULTS: We observed that the addition of inhibitor resulted in 2.1-fold enrichment of spontaneously beating human embryoid bodies (hEB) at 21 days of differentiation, and that 25% of treated cells expressed cardiac-specific α-myosin heavy chain. This effect was dependent on the stage of differentiation at which the inhibitor was introduced. Immunostaining and teratoma formation assays demonstrated that the inhibitor did not affect hESC pluripotency; however, treated hESC gave rise to hCM exhibiting increased expression of sarcomeric proteins, including cardiac troponin T, myosin light chain and α-myosin heavy chain. This was consistent with significantly increased numbers of myofibrillar bundles and the appearance of nascent Z-bodies at earlier time-points in treated hCM. Treated hEB also demonstrated a normal karyotype by array comparative genomic hybridization and viability in vivo following injection into mouse myocardium. CONCLUSIONS: These studies demonstrate that p38MAPK inhibition accelerates directed hCM differentiation from hESC, and that this effect is developmental stage-specific. The use of this inhibitor should improve our ability to generate hESC-derived hCM for cell-based therapy.
BACKGROUND AIMS: Heart failure therapy with human embryonic stem cell (hESC)-derived cardiomyocytes (hCM) has been limited by the low rate of spontaneous hCM differentiation. As others have shown that p38 mitogen-activated protein kinase (p38MAPK) directs neurogenesis from mouse embryonic stem cells, we investigated whether the p38MAPK inhibitor, SB203580, might influence hCM differentiation. METHODS: We treated differentiating hESC with SB203580 at specific time-points, and used flow cytometry, immunocytochemistry, quantitative real-time (RT)-polymerase chain reaction (PCR), teratoma formation and transmission electron microscopy to evaluate cardiomyocyte formation. RESULTS: We observed that the addition of inhibitor resulted in 2.1-fold enrichment of spontaneously beating human embryoid bodies (hEB) at 21 days of differentiation, and that 25% of treated cells expressed cardiac-specific α-myosin heavy chain. This effect was dependent on the stage of differentiation at which the inhibitor was introduced. Immunostaining and teratoma formation assays demonstrated that the inhibitor did not affect hESC pluripotency; however, treated hESC gave rise to hCM exhibiting increased expression of sarcomeric proteins, including cardiac troponin T, myosin light chain and α-myosin heavy chain. This was consistent with significantly increased numbers of myofibrillar bundles and the appearance of nascent Z-bodies at earlier time-points in treated hCM. Treated hEB also demonstrated a normal karyotype by array comparative genomic hybridization and viability in vivo following injection into mouse myocardium. CONCLUSIONS: These studies demonstrate that p38MAPK inhibition accelerates directed hCM differentiation from hESC, and that this effect is developmental stage-specific. The use of this inhibitor should improve our ability to generate hESC-derived hCM for cell-based therapy.
Authors: Jonathan S Draper; Kath Smith; Paul Gokhale; Harry D Moore; Edna Maltby; Julie Johnson; Lorraine Meisner; Thomas P Zwaka; James A Thomson; Peter W Andrews Journal: Nat Biotechnol Date: 2003-12-07 Impact factor: 54.908
Authors: Christine Mummery; Dorien Ward-van Oostwaard; Pieter Doevendans; Rene Spijker; Stieneke van den Brink; Rutger Hassink; Marcel van der Heyden; Tobias Opthof; Martin Pera; Aart Brutel de la Riviere; Robert Passier; Leon Tertoolen Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Maisam M Mitalipova; Raj R Rao; Deborah M Hoyer; Julie A Johnson; Lorraine F Meisner; Karen L Jones; Stephen Dalton; Steven L Stice Journal: Nat Biotechnol Date: 2005-01 Impact factor: 54.908
Authors: Felix B Engel; Michael Schebesta; Mychelle T Duong; Gang Lu; Shuxun Ren; Jeffery B Madwed; Huiping Jiang; Yibin Wang; Mark T Keating Journal: Genes Dev Date: 2005-05-03 Impact factor: 11.361
Authors: Tian Xue; Hee Cheol Cho; Fadi G Akar; Suk-Ying Tsang; Steven P Jones; Eduardo Marbán; Gordon F Tomaselli; Ronald A Li Journal: Circulation Date: 2004-12-20 Impact factor: 29.690
Authors: I Kehat; D Kenyagin-Karsenti; M Snir; H Segev; M Amit; A Gepstein; E Livne; O Binah; J Itskovitz-Eldor; L Gepstein Journal: J Clin Invest Date: 2001-08 Impact factor: 14.808
Authors: Yerem Yeghiazarians; Meenakshi Gaur; Yan Zhang; Richard E Sievers; Carissa Ritner; Megha Prasad; Andrew Boyle; Harold S Bernstein Journal: Cytotherapy Date: 2011-10-31 Impact factor: 5.414
Authors: Pieterjan Dierickx; Pieter A Doevendans; Niels Geijsen; Linda W van Laake Journal: J Cardiovasc Transl Res Date: 2012-07-18 Impact factor: 4.132
Authors: Christopher Barry; Matthew T Schmitz; Peng Jiang; Michael P Schwartz; Bret M Duffin; Scott Swanson; Rhonda Bacher; Jennifer M Bolin; Angela L Elwell; Brian E McIntosh; Ron Stewart; James A Thomson Journal: Dev Biol Date: 2017-02-06 Impact factor: 3.582
Authors: Adriana Blazeski; Renjun Zhu; David W Hunter; Seth H Weinberg; Kenneth R Boheler; Elias T Zambidis; Leslie Tung Journal: Prog Biophys Mol Biol Date: 2012-08-07 Impact factor: 3.667